<DOC>
	<DOCNO>NCT00770081</DOCNO>
	<brief_summary>This clinical trial design provide additional information safety tolerability vildagliptin ( 50 mg daily ( qd ) ) sitagliptin ( 25 mg qd ) use patient type 2 diabetes mellitus ( T2DM ) severe renal insufficiency ( Glomerular filtration rate ( GFR ) &lt; 30 mL/min ) period 52 week .</brief_summary>
	<brief_title>Safety Tolerability Vildagliptin Versus Sitagliptin Patients With Type 2 Diabetes Severe Renal Insufficiency ( 28-week Extension Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Complete core study consent extension Patient unable comply core study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>